Diabetes Is ProfitableA structural investigation

Related Research and Scholarly Context

The Scholarship Behind “Diabetes Is Profitable”

Five closely aligned publications support the major links in the argument. None tests the complete incentive system as one unified hypothesis.

Research synthesis by Tim Barrie · August 6, 2026

What the literature supports

Commercial structures help expand disease-promoting food exposure upstream and create expanding markets for diabetes drugs, devices, monitoring and treatment downstream.

What remains a synthesis

The claim that these separately documented mechanisms form one connected incentive system is the report’s reasoned conclusion—not the direct finding of a single experiment.

The Central Finding

The argument in Diabetes Is Profitable is not unsupported and it is not simply a restatement of one existing paper. It joins research that has largely developed in two separate academic compartments.

One body of scholarship studies the commercial food system: how investor pressure, corporate growth, product strategy, marketing, distribution and political influence expand the sale and consumption of ultra-processed foods and beverages. A second body examines how diabetes, prediabetes and perceived future risk create markets for drugs, devices, monitoring and clinical intervention.

The literature supports the major links in the chain. The investigation’s contribution is identifying the chain as one connected incentive system.

This distinction matters. The five publications below make the combined thesis more credible, but they do not eliminate the need to label the final connection accurately as a synthesis and causal inference.

Two Halves of the Same System

Upstream

Profitable exposure

Wood, Moodie and Stuckler examine why large food corporations depend on, expand and politically defend markets for highly profitable ultra-processed products.

Downstream

Profitable treatment and risk

Hunt and Brantly examine how diagnostic thresholds, risk categories, pharmaceuticals, devices and monitoring can enlarge diabetes-related markets.

Publication Main mechanism examined Role in the thesis
Wood et al. (2023) Financialisation and shareholder primacy in ultra-processed-food corporations Why corporate governance can favor profitable product growth over healthier diets
Moodie et al. (2021) Market expansion and political practices of transnational food corporations How exposure is produced, distributed, marketed and defended at scale
Stuckler et al. (2012) Multinational market penetration and unhealthy-commodity consumption Why economic development alone does not explain the growth in exposure
Hunt et al. (2021) Diabetes and prediabetes guidelines under alleged industry influence How eligible treatment populations and drug markets may expand
Brantly (2025) Biomedicalization of risk through drugs, devices and monitoring How commercial markets can extend into pre-diagnostic populations

The Five Closest Publications

UpstreamExploratory mixed-methods research2023

1. What Is the Purpose of Ultra-Processed Food?

Wood and colleagues examined financial data from U.S.-listed food and agricultural corporations, ownership and proxy-voting data, and academic and grey literature. They found that corporations heavily dependent on ultra-processed foods had increasingly transferred money to shareholders relative to revenue, while investors seeking healthier population diets had limited influence.

Why it belongs: This is the closest match to the investigation’s corporate-governance mechanism. It links shareholder primacy and investor pressure to the conduct of major ultra-processed-food companies and concludes that these forces undermine healthier population diets.

Supports The proposition that profitable food exposure is shaped by governance, finance and investor priorities—not merely by isolated consumer choices.
Does not establish That these corporate structures cause every case of type 2 diabetes or coordinate with treatment industries.

Read the open-access paper →

UpstreamMixed-methods synthesis review2021

2. Ultra-Processed Profits

Moodie and colleagues used sales data, academic, market and grey literature, and three country cases to examine the expansion of ultra-processed foods in middle-income countries. Their analysis covers production, distribution, marketing, retail, political activity and public-health resistance.

Why it belongs: The paper shows the machinery through which Big Food can turn corporate resources and political influence into growing consumption. It helps explain how commercially favored products become a population-level environment.

Supports The proposition that exposure is commercially produced and expanded through coordinated activity within food corporations and markets.
Does not establish The downstream treatment-profit mechanism or prove that all ultra-processed products have identical health effects.

Read the paper →

UpstreamExternally peer-reviewed policy forum2012

3. Manufacturing Epidemics

Stuckler and colleagues compared international patterns in the consumption of processed foods, soft drinks, alcohol and tobacco. They found that rapid growth in unhealthy-commodity consumption was especially associated with multinational market penetration, foreign direct investment and trade conditions—not with economic growth or urbanization alone.

Why it belongs: The paper explicitly treats multinational producers as important vectors in the spread of noncommunicable-disease risks. It also explains why unhealthy commodities are commercially attractive: low production costs, long shelf lives and high retail value.

Supports The proposition that global producers and market structures can manufacture and scale harmful exposure without centrally planning a disease epidemic.
Does not establish Individual-level causation from a particular product to a particular diabetes diagnosis; its principal analysis is population-level.

Read the open-access paper →

DownstreamOriginal bioethical research2021

4. Are Corporations Re-Defining Illness and Health?

Hunt and colleagues reviewed four decades of changes to type 2 diabetes and prediabetes screening, diagnosis and treatment guidelines. The authors argue that expanded thresholds and recommendations substantially enlarged the population prescribed diabetes drugs under conditions of pervasive pharmaceutical-industry influence.

Why it belongs: This is the closest publication to the investigation’s downstream claim that diabetes can become a larger commercial market not only through rising disease prevalence, but also through expanded definitions, targets and treatment eligibility.

Supports A serious, documented scholarly argument that commercial influence may shape the boundaries of illness and treatment markets.
Does not establish A settled clinical consensus that revised guidelines lack benefit. These are the authors’ contested conclusions and must be presented as such.

Read the abstract and publication record →

DownstreamCritical conceptual analysis2025

5. Global Implications of Diabetes Biomedicalization

Brantly examines how drugs, continuous glucose monitors and risk classifications extend diabetes-related intervention into pre-diagnostic populations. The paper uses type 1 diabetes prevention and glucose monitoring among people without a diabetes diagnosis to analyze a broader expansion of pharmaceutical and device markets around future risk.

Why it belongs: It directly describes diabetes as both a health burden and a growing commercial domain. More importantly, it explains how risk itself can become a market before symptomatic disease is present.

Supports The broader downstream mechanism: monitoring, treatment and commercial opportunity can expand beyond diagnosed disease into risk-defined populations.
Does not establish The biological origins of the type 2 diabetes epidemic. Its examples include type 1 diabetes and non-diagnostic glucose monitoring.

Read the open-access paper →

What This Investigation Adds

The five papers are not interchangeable. The first three explain different parts of the upstream commercial-food mechanism. The last two examine the downstream expansion of diabetes-related treatment and risk markets.

Corporate structures reward the production and expansion of disease-promoting exposure upstream; the chronic illness that follows creates additional and more durable markets downstream; while successful population-level prevention threatens revenue on both sides and has no comparably powerful commercial constituency.

No publication above tests that complete proposition as a single causal system. The distinctive contribution of Diabetes Is Profitable is to connect the two bodies of scholarship and explain why the combined result requires no conspiracy, coordination or intention to cause disease. Each organization need only respond to the incentives immediately in front of it.

Limits That Must Remain Visible

Broader scholarly context. This work sits within the established field of the commercial determinants of health: the conditions, actions and omissions by commercial actors that affect health. A 2020 systematic review found that the literature already uses concepts such as industrial epidemics, profit-driven disease and corporation-induced disease. That field supports the framework, while the five papers above are the closest matches to its diabetes-specific upstream and downstream components.

References

  1. Wood, B., Robinson, E., Baker, P., et al. (2023). “What is the purpose of ultra-processed food? An exploratory analysis of the financialisation of ultra-processed food corporations and implications for public health.” Globalization and Health, 19, article 85. https://doi.org/10.1186/s12992-023-00990-1
  2. Moodie, R., Bennett, E., Kwong, E. J. L., Santos, T. M., Pratiwi, L., Williams, J., & Baker, P. (2021). “Ultra-Processed Profits: The Political Economy of Countering the Global Spread of Ultra-Processed Foods.” International Journal of Health Policy and Management, 10, 968–982. https://doi.org/10.34172/ijhpm.2021.45
  3. Stuckler, D., McKee, M., Ebrahim, S., & Basu, S. (2012). “Manufacturing Epidemics: The Role of Global Producers in Increased Consumption of Unhealthy Commodities Including Processed Foods, Alcohol, and Tobacco.” PLOS Medicine, 9(6), e1001235. https://doi.org/10.1371/journal.pmed.1001235
  4. Hunt, L. M., Arndt, E. A., Bell, H. S., et al. (2021). “Are Corporations Re-Defining Illness and Health? The Diabetes Epidemic, Goal Numbers, and Blockbuster Drugs.” Journal of Bioethical Inquiry, 18, 477–497. https://doi.org/10.1007/s11673-021-10119-x
  5. Brantly, N. D. (2025). “Global implications of diabetes biomedicalization.” Social Theory & Health, 23, article 21. https://doi.org/10.1057/s41285-025-00240-x
Read the full evidence and methodology Read the accessible investigation